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ABSTRACT 
The goal of CERVIS is to make a substantial, positive impact in the cervical cancer screening 
space through the development of a minimally invasive, cost effective solution that enables 
women in low-resource settings to test for cervical cancer on a frugal and effective platform. In 
the developed world, there are a variety of options that can aid in early detection, including Pap 
smears. However, due to the high cost and laboratory requirements that accompany this 
procedure, women in low-resource settings rarely have access to this preventative care or 
regular screenings for cervical cancer. Using new research about the changes in the vaginal 
microbiome, CERVIS aims to create a frugal, visual diagnostic screening tool for early stage 
cervical cancer as an alternative to the existing expensive, invasive, and clinic-dependent 
methods. Outcomes will be measured by partnering with a Kenyan NGO to collect data from 
several clinics. 
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CHAPTER 1. INTRODUCTION 
1.1 Background 
Cervical cancer accounts for 6.6% of all female cancers worldwide. The WHO states that 90% 
cervical cancer-related deaths occur in low and middle income countries, most of which could be 
prevented by screening and early diagnosis (WHO, 2018). Additionally, the link between Human 
Papillomavirus (HPV) and cervical cancer has been thoroughly established. Around one-half of 
individuals diagnosed with HPV infections have high-risk infections. HPV 16 and HPV 18, two 
of the most common strains of high risk HPV cause 70% of cervical cancers. 
Current HPV infection and cervical cancer screening identify DNA and protein biomarkers from 
cervical samples using expensive, high tech devices (see 1.2 Review of Field). These factors 
limit test feasibility in low-resource areas, creating a need for new screening technologies. 
Team CERVIS , a group of undergraduate students from Santa Clara University departments of 1
Bioengineering and Public Health, are building on promising research related to changes in the 
vaginal flora to meet this need. Emerging research demonstrates the link between vaginal flora 
and cervical cancer, which has informed the device design. Specifically, ​Fusobacteria ​is 
undetectable in swabs taken from a healthy vagina but constitutes approximately 17% of bacteria 
in cervical cancer vaginal samples ( ​Audirac-Chalifour et al., 2016 ​). Despite a more robust library 
of scientific journal articles linking protein biomarkers to cervical cancer, the possibility of 
bacteria as a biomarker was explored as a cheaper and easier method for cervical cancer 
screening. Our goal is to use  this research to design an early-stage cervical cancer screening test 
using microbial cultivation techniques to consistently and accurately detect the presence of 
Fusobacteria. 
1 Cervical Cancer Early Response Visual Identification System 
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1.2 Review of Field & Critiques of Current Technology 
The key to preventing and addressing cervical cancer development is preventative medicine and 
routine screenings. The HPV vaccination and Pap smear are most common in developed nations 
while Visual Inspection with Acetic acid (VIA) is used more often in poorly resourced areas 
(Gaffikin, 1999). 
Pap smears and colposcopies ​ are the most common cervical cancer screening methods used in 
developed nations to accurately detect both precancerous and cancerous cellular processes within 
a swab sample of the cervix (Markovic, 1998). Analysis of Pap smears requires a high degree of 
technical and clinical knowledge to identify and swab the cervix correctly to interpret  sample 
results for appropriate diagnosis . Additionally, expensive equipment to analyze the sample and 
laboratory access is required for proper and effective analysis. These procedures have a high 
number of false positives. Finally, from an individual patient standpoint, Pap smears and 
colposcopy are invasive, painful, and costly (Markovic, 1998).  
HPV vaccinations, ​in combination with cancer screenings, are the greatest preventative measure 
against cervical cancer (WHO, 2018). FDA approved vaccinations including Gardasil and 
Cervarix have been found to be nearly 100% effective at preventing cervical infections of HPV 
16/18, the two strains most commonly associated with the development of cervical cancer. The 
Center for Disease Control (CDC) recommends that all women through the age of 26 and all men 
through the age of 21 start the vaccination series between the ages of 11-15. While the HPV 
vaccine provides protection from HPV infection, it does not offer any therapeutic treatment of 
the virus or cervical cancer. Additionally, social stigmas prevent many from getting vaccinated. 
The vaccine, delivered in a two or three-part series, must be delivered by a health care 
professional in a clinical setting, making it difficult for those with limited access to clinics and 
hospitals to receive the full dose of the vaccine. Finally, the vaccine is expensive, costing up to 
$330 for an complete dosage.  
Visual Inspection with Acetic Acid (VIA)​ of the cervix is an inexpensive screening method in 
poorly resourced areas (Gaffikin, 1999). Trained health workers and nurses work in mobile 
screening camps in low income areas to perform this screening test. The test is invasive and can 
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cause some discomfort similar to the Pap smear method because of the insertion of a 
self-retaining vaginal speculum. After insertion, acetic acid is applied to the cervix and watched 
for a reaction between the suspected lesion and the acetic acid (Poli, 2015). Similar to the 
limitations of the previous devices, VIA also requires a high degree of technical knowledge to 
properly administer the screening, must be done in a clinical environment, and is highly invasive. 
If the test is not administered properly, bubbles may still form, resulting in false positives.  
Nurx HPV Test ​tests for molecular markers in cervical tumorigenesis, however, this test 
remains out of reach financially for clinics in many LMICs. NurX uses nucleic acid based HPV 
screening to test for the presence of high risk strains of the virus. While this method is accurate 
and highly specific, it relies on expensive pieces of laboratory equipment that require technical 
expertise to operate and understand machine output. ( ​Nurx™)​.  
Roche CINtec PLUS Cytology​ is a qualitative immunohistochemistry (IHC) test using the p16 
biomarker, which is a cancer biomarker specifically linked to cervical cancer. The test is 
conducted using microscopic assessment of ​p16​INK4a​ protein in formalin-fixed, 
paraffin-embedded (FFPE) cervical punch biopsy tissues. The test confirms cervical 
abnormalities based on hematoxylin and eosin (H&E) stained slides. This test is a more specific 
alternative to Pap smear, but is invasive, expensive, requires a clinician, and results in high rates 
of false positives (CINtec® PLUS Cytology). 
The table below summarizes the benefits and limitations of each of the current innovations to 
combat cervical cancer that were mentioned previously. 
Table 1: Current Technologies in CC/HPV Screening  
Device Benefits Limitations  
Pap smear & Colposcopy Accuracy Invasive 
Expensive lab equipment 
required for testing 
Clinical and technical 
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expertise required for analysis 
Visual Inspection with Acetic 
Acid (VIA) 
Inexpensive  
Primary screening technique 
in low resource nations  
Invasive  
Moderate technical expertise 
required 
Low sensitivity if 
administered incorrectly 
Roche CINtec PLUS 
Cytology 
Specific for Ki-67 and p16 
markers of HPV infection 
Invasive 
Multiple clinic visits 
Specific for ≥CIN-2 
Technical expertise required 
Nurx HPV test Ease of use 
No clinical training required 
to administer the test 
Tests only for HPV, not 
directly for cervical cancer  
Expensive lab equipment 
required for testing 
Technical expertise required 
for analysis 
 
The limitations of these current innovations highlight the need for a cost effective medical 
screening device that enables women in low resource settings, without access to high-grade 
medical care, to accurately test for cervical cancer. The device must be non-invasive, making it 
easier to implement on a global scale. Additionally, the results of the screening should be simply 
interpreted and analyzed by individuals with little to no technical medical background. 
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1.3 Microbiome Screening Potential  
The human microbiome contains a vast diversity of microorganisms that play critical roles in 
maintaining health. Each individual has a unique microbiome, and the differences in microbial 
populations can make people more resistant or susceptible to illness (Huang, 2018). By 
understanding the microbial communities that make up a healthy microbiome and the factors that 
affect microbial composition, new ways to diagnose, treat, and prevent a variety of human 
diseases are being considered. 
The vagina is a complex, dynamic microbial niche within the human microbiome that is 
influenced by age, sexual activity, and other lifestyle factors (Huang, 2018). In general, during 
female maturation, the ratio of aerobic to anaerobic bacteria increases due to changes in vaginal 
pH, hormones, and sexual activity. In women of reproductive age (15-49), the average ratio of 
aerobic to anaerobic vaginal bacteria is approximately 1:10 (Gorbach et. al). Below is a table 
highlighting some of the principle microbiota within a healthy female genital tract. 
Table 2. Select Normal Vaginal Flora 
Species O​2​ preference Gram 
stain (+/-) 
Morphology Catalase 
test (+/-) 
Prevalence 
in vaginal 
flora (%) ​1 
Lactobacillus Aerotolerant 
anaerobe 
+ Rods - 60 
Gardnerella 
vaginalis 
Facultative 
anaerobe 
Gram 
variable 
Short Rods - 7.2 
Streptococcus 
Agalactiae 
Microaerophile + Cocci - 34 
Diphtheroids Facultative 
anaerobe 
+ Rod + 40 
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Notes: 
1)         ​Values reported are mean values for analyzed vaginal swabs. Source: (Hutt et. al, 2001) 
 
Prior understanding of vaginal health focused on cell turnover, mucus production, and local 
immune defenses as important players in the maintenance of a normal vagina (Reid, 2018). 
Recently, it has become more clear that bacteria within the vagina also play protective roles and 
can contribute to a variety of diseases.  
1.4 Significance of Project 
Cervical cancer is a women’s health issue on a global scale with an estimated 530,000 women 
diagnosed each year, according to the World Health Organization (WHO 2018). HPV 
vaccinations are one of the strongest available measures against cervical cancer especially when 
used in combination with accurate and routine screening methods such as a Pap smear. These 
methods, though commonly used in the developing world, are not widely available to women in 
poorly resourced areas for barriers previously discussed.  
Additionally, HPV is a viral infection with more than 30-40 subtypes (Dixit, 2011). The most 
common oncogenic subtypes of HPV, HPV16 and HPV18, produce E6 and E7 oncoproteins. 
Currently, DNA and RNA based tests that require the use of polymerase chain reaction (PCR) 
are most commonly used to diagnose HPV (Engstrom-MeInyx, 2014). To eliminate the need for 
PCR, the proposed device uses a bacterial biomarker to produce a binary output based on the 
work of ​Audirac-Chalifour et al., ​ thus contributing to the field of microbiology (2016).  
In 2008, the National Institutes of Health (NIH) launched the human microbiome project to 
understand the microbial microenvironments in the human body and how these microbial flora 
contribute to human health and disease (Gevers, 2012). The vaginal microbiome was explored to 
gain insight into the means by which vaginal microbiomes fight against urogenital diseases. 
Using pyrosequencing of barcoded 16s rRNA genes, the researchers identified communities that 
were clustered into five groups. Although this project produced a baseline for understanding the 
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healthy vaginal microbial community, questions remain as to how to further quantify and define 
“healthy.”  
Researchers under the guidance of Dr. Ami Bhatt, Stanford University’s Director of Global 
Oncology, are looking beyond the results from the human microbiome project to understand 
variations in the microbiome resulting from factors including location and lifestyle. Bhatt’s 
research aims to draw conclusions on the microbiome that can be broadly applied, focusing on 
populations living in areas that are in the process of industrialization gaining access to new, 
processed foods to get a holistic look on the microbiome and its relation to health. Once 
published, research from this study will influence how CERVIS is used in the field.  
The CERVIS project is novel because it contributes to the growing field of microbiology, 
looking not at traditional protein biomarkers that require expensive analytical techniques but at a 
bacterial biomarker that is upregulated in the presence of precancer and cervical cancer. By 
designing a test capable of screening for the presence of ​Fusobacterium ​spp., a screening method 
for implementation in low- and middle-income countries around the world will improve access 
to care and empower women, reducing the burden of disease.  
 ​1.5 Proposed Goals, Objectives, and Expected Results 
During the Fall of 2018, specific goals, objectives, and expected results were created and agreed 
upon by all members of the team. These goals dynamically shifted throughout the year, as 
decisions were made about the biomarker of interest and the intended target community. Table A 
outlines the initial goals, objectives, and expected results as they were understood during the 
early stages of the project.  
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Chapter 2: PROJECT OVERVIEW  
2.1 Target Population 
Cervical cancer ranks as the first most common female cancer in Kenyan women ages 15 to 44 
years old with over 5,000 cases diagnosed annually ( ​De Sanjosé et al., 2007 ​). The current target 
population for CERVIS pilot testing and implementation is Kenya, due to the high incidence and 
mortality rate of cervical cancer. Kenya also has an extremely high incidence rate of high risk 
strains, HPV 16/18, as it is more than double that of the United States and other developed 
countries. Currently, 68% of Kenyan women diagnosed with cervical cancer will die from the 
disease, making cervical cancer the first leading cause of cancer death in women ( ​De Sanjosé et 
al., 2007 ​). Many of these deaths could be prevented by HPV screening and early diagnosis of 
cervical cancer; however there is a lack of a low cost, non-invasive screening for low resource 
settings (Coleman et al., 2016). 
2.1.1 Customer Needs & Cultural Relevance  
Cervical cancer is the leading cause of cancer deaths in sub-Saharan Africa (WHO, 2018), and 
the incidence is likely underreported due to poor cancer registration (Kimani, Sherif, & Bashir, 
2012). Cervical cancer screening methods including Pap smear and VIA have significantly 
reduced the burden of disease in several sub-Saharan African countries, and the “screen-and 
treat” approach allows for women who test positive to receive cryotherapy immediately 
following diagnosis (Coleman et al., 2016). 
Although these methods are available in Kenya as part of the Ministry of Health’s National 
Cervical ​Cancer Prevention Strategic Plan from 2002-2006, adoption remains low because these 
methods are invasive, they have difficulty navigating cultural barriers, and most women do not 
seek out medical treatment until they suspect a health issue (WHO, 2018). ​ Additionally, the 
negative stigma about cervical cancer and fear of screening results prevent screening methods 
from being more widely employed. If screening and treatment for cervical cancer does not 
increase, the number of cervical cancer deaths is estimated to double in Kenya by 2025, 
demonstrating the need to educate women about cervical cancer screening and treatment options 
(Sudenga, 2013). Increasing smartphone usage rates in Kenya provides a technological platform 
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that can reduce prevailing barriers and thus the burden of disease (Poushter, 2016). Additionally, 
eliminating the need for women to travel to the clinic by focusing efforts on designing 
in-the-field screening methods has the potential to address cervical cancer deaths in low and 
middle income countries.  
2.2 Project Components  
A list of device criteria were defined based on the culturing conditions of the selected bacterial 
biomarker and the development of a screening device (Figure 1). First, in order to create a binary 
output, meaning the test detects the absence or presence of this species of bacteria, the device 
must be capable of selectively growing the bacteria of interest from a patient sample. Secondly, 
the device must maintain an anaerobic environment during the growth period because 
Fusobacterium ​is unable to grow in the presence of oxygen. And finally, the device must 
seamlessly incorporate the patients sample to allow for ease of use and result interpretation.  
These criteria were organized depending of the form of the device or the function of the device. 
Experiments were designed to address each of these criteria, and the results of these experiments 
ultimately informed the design of the proposed screening device.  
 
Figure 1: Subsystems Overview  
2.2.1 Bacterial Biomarkers of Interest  
Proteins were originally explored as biomarkers indicative of cervical cancer for this project. 
DNA amplification arose as an issue when dealing with these biomarkers because DNA 
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Selective 
Anaerobic 
Sampling 
Mechanism 
Self-Contained 
Tube 
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amplification is done by polymerase chain reaction (PCR) and subsequent analysis by 
sequencing or gel electrophoresis. PCR uses a strand of template DNA, the enzyme taq 
polymerase, primers, and exposure to repeated cycles of heating and cooling, which is done 
using a PCR machine that typically costs between $800 and $20,000. The primers, template 
DNA, and enzyme must be preserved by refrigeration.  
Because CERVIS is intended for use in low- and middle-income countries, this route proved 
ineffective based on the need for expensive laboratory equipment and refrigeration. The link 
between vaginal microbiome diversity or concentrations and their association with HPV, 
precancerous lesions, and cervical cancer was explored as a promising alternative to protein 
biomarkers ( ​Audirac-Chalifour et al., 2016 ​). Additionally, using bacterial biomarkers showed 
potential for cheaper and easier culturing methods. ​Lactobacillus ​and ​Fusobacterium ​were 
explored as potential target biomarkers for CERVIS.  
2.2.1.1 Lactobacillus  
Lactobacillus ​ is often the predominant species in the normal vaginal microbiome 
( ​Audirac-Chalifour et al., 2016) ​. Given the abundance of ​Lactobacillus ​in a healthy vaginal 
microbiome, ​Lactobacillus ​was chosen to test the efficacy of using bacterial biomarkers. Initial 
experiments were designed to isolate lactobacillus from the vaginal microbiome. The purpose of 
these experiments was to both learn microbiology laboratory techniques and understand the 
difficulty in selecting against related species for the isolation of one particular bacteria. 
This species plays a critical role in regulating the presence of other vaginal flora as well as 
protecting the host from pathogens (Larsen and Monif, 2001). Mechanisms for pathogen and 
microbial inhibition have been attributed to the ability of ​Lactobacillus ​ to produce 
hydrogen-peroxide, an oxidizing agent that disrupts the plasma membrane of certain microbes, as 
well as lactic acid which can alter the pH within the vagina (Larsen and Monif, 2001). Previous 
studies show a significant correlation between absence of hydrogen-peroxide producing 
Lactobacilli and colonization by bacteria associated with vaginal disease as well as an increased 
abundance of Lactobacilli in in young adolescents (Hiller et. al). Both of these findings point to 
the importance of ​Lactobacillus ​ in defending the host from potential pathogens. 
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Previous research has identified Lactobacilli at the genus level by gram stain, colony 
morphology, and catalase test (​Hütt​ et. al, 2016). Specifically, ​Lactobacilli ​are gram positive, rod 
shaped, and produce a negative catalase test (​Hütt​ et. al, 2016).  
2.2.1.2 Fusobacteria 
Studies show that​ Fusobacterium ​spp. is undetectable in vaginal swabs from a healthy vagina but 
constitutes approximately 17% of bacteria in a vaginal sample from a cervical cancer patient 
(​Audirac-Chalifour et al., 2016​). Based on this information, this bacteria species was chosen as 
the final bacterial biomarker used in CERVIS.  
Fusobacterium ​spp. is an anaerobic, gram-negative bacteria ​usually absent in healthy tissue but 
upregulated in instances of disease. ​Fusobacterium nucleatum is associated with inflammatory 
diseases including ​appendicitis and ulcerative colitis, as well as multiple cancers, including 
colorectal, oropharyngeal, and cervical cancers (​Audirac-Chalifour et al., 2016​). 
Our team selected a strain of ​F. nucleatum ​and​ F. necrophorum​ to investigate practical 
field-based cultivation methods for obligate anaerobes. By conducting a series of experiments, a 
set of criteria was developed for the optimum culturing of fusobacterium nucleatum and 
necrophorum without an anaerobic hood, which is unavailable in frugal contexts.  
 
Figure 2: The Link between ​Fusobacterium ​and Cervical Cancer (Astride 
Audirac-Chalifour, 2016) ​.  
2.2.3 Physical Manifestation of the Assay 
2.2.3.1 Device Format  
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The assay development was an iterative process. As initial laboratory results were collected, the 
anaerobic requirement for the future prototype was realized. In creating initial sketches, the 
designs took two forms, a plate and tube design (Figure 3). The tube design with semi-solid 
media was determined the best option for maintaining an anaerobic environment for 
Fusobacterium ​growth and detection. The tube design with the swab inserted and twist helped 
maintain an anaerobic environment capable of growing fusobacteria. To justify the final device 
format, questions were answered about the density of the media and the shape of the device for 
anaerobic maintenance and optimal growth conditions.  
 
The plate design reduced the possibility of creating a truly anaerobic environment. Creating a 
sealed enclosure that made the entire chamber remain anaerobic posed a challenge because a 
larger surface area would be exposed to oxygen upon sample introduction. Furthermore, the 
application of the plate design required a more in depth understanding of microbiology and of 
microbiology techniques to properly streak the plate.  
Plate Design   Tube Design 
  
Figure 3: Initial Prototype Ideations 
2.2.3.2 Swab Collection  
To determine the optimal collection method, five cytology applicators- the Cervex brush, the 
cervical spatula, the cotton swab, the polyester swab, and the bristle brush- were chosen to 
measure the amount of oxygen introduced into a semi-solid media in a closed glass tube. In 
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addition to oxygen exposure, the swabs were each evaluated based on criteria of size, toxicity, 
and sample collection. 
2.2.4 Growth Media 
To create the media for the growth of ​Fusobacterium ​, several conditions were required. The 
media had to be nutrient-rich to support the growth of bacteria and had to be selective for the 
growth of ​Fusobacterium ​. Additionally, the media had to be transparent in order to easily 
observe growth. Finally, the media, in combination with the device form, was required to 
maintain anaerobic conditions to support the growth of fusobacterium, an obligate anaerobe. To 
meet these criteria, several ingredients were included in the media: Brain Heart Infusion broth, 
antibiotics, and Gelrite. 
The media recipe was tested for functionality and altered to improve results in two different 
iterations. The results of each iteration and the criteria for altering the recipe are discussed in 4.2. 
2.2.4.1 Anaerobic Conditions 
Since ​Fusobacterium ​is an obligate anaerobe, the media also needed to be able to maintain 
anaerobic conditions within the tube. Currently, it is challenging to keep liquid media tubes free 
of oxygen because it is more easily mixed throughout the media even if only the surface becomes 
exposed to oxygen (See 2.2.3.2). To achieve a semi-solid consistency, Gelrite was added to the 
media. Gelrite was used instead of agar because it allows the same consistency as agar but 
prevents cloudiness when the media is poured. Oxygen inevitably enters the tube when it is 
opened for sample penetration. While the semisolid media prevents the oxygen from spreading 
throughout the media, it does not actively reduce the amount of oxygen in the media. To address 
this concern, an oxygen scavenger was incorporated into the CERVIS 1.0 formula. Additionally, 
an oxygen indicator was added to the media to identify oxygen exposure. When oxygen enters 
the system, the resazurin reacts with the oxygen to turn blue, showing exactly where oxygen has 
entered the media. This allowed close monitoring of the anaerobicity of the media. 
2.2.6 ​Educational Component 
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An educational component teaching women about their anatomy, the risks of cervical cancer, 
and the importance of screening will be developed with the help of local community members 
for ensured cultural relevance and incorporated into the device implementation strategy. This 
program will extend to both patients and providers to increase screening uptake by the women 
living in the community and minimize the risk of false positive results. This is an important step 
in navigating cultural barriers and ensuring that the device is implemented in the most effective 
and ethical way. This component was outside the scope of the project for this year, but a 
preliminary outline of next steps is discussed in Chapter 6.  
2.3 ​Team and Project Management 
The project team is composed of four Santa Clara University (SCU) faculty members, four 
bioengineering students, and three public health students from the Engineering World Health 
(EWH) partnership. The faculty advisors are Dr. Prashanth Asuri, Dr. Michele Parker, Dr. Craig 
Stephens, and Dr. Tracy Ruscetti. Dr. Prashanth Asuri has served as a Bioengineering and 
Bioinnovation advisor. Dr. Michele Parker has served as a public Health advisor and a mentor to 
the Engineering World Health aspect of the project. Dr. Craig Stephens has served as a 
Microbiology advisor and mentored the students in common microbiology techniques. 
Additionally, Dr. Stephens provided the students with lab space and supplies. Finally, Dr. Tracy 
Ruscetti has also served as a Microbiology advisor, training the students in the anaerobic 
chamber and assisting with experimental design. The public health students that partnered with 
the bioengineering students through EWH are Dave Heil, Nicola Gerbino, and Mason Seeley. 
The project originally stemmed from the work of a 2017-2018 senior design group. Within the 
bioengineering student group, all experimental design, presentations, team member 
communication, company visits, and lab work were completed as a team. In terms of individual 
roles, Claire Hultquist managed supplies orders, Julia Lanoha planned School of Engineering 
showcasing dates, Rosie McDonagh organized meeting notes, and Hallie McNamara was the 
lead contact with EWH.  
2.3.1 ​Budget 
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The funds for necessary supplies for experimentation and development of the frugal screening 
biodevice were requested from the Santa Clara University Undergraduate Programs. The 
awarded funding for the Frugal Cervical Cancer screening is summarized in Table B found in the 
appendix. Additionally, a detailed outline of the expenditures of the project totalling $1,230.27 
can be found in Table C in the appendix.  
2.3.2 ​Timeline  
Reference appendix A for a complete overview of completed action items for the CERVIS 
project between Fall 2018 and Summer 2019.  
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CHAPTER 3: Bacteria Biomarkers of Interest (Subsystem A) 
3.1 Introduction 
Up until the 1970s, there was poor characterization of the vaginal microbiome due to the narrow 
range of media and oxygen levels that allow for cultivation of these bacteria (Larsen and Monif, 
2001). Today, over 150 different bacterial species have been characterized as populates of the 
vagina that participate in many interactions within this ecosystem (Larsen and Monif, 2001).  
Being able to rapidly recognize changes in vaginal flora and how this corresponds with specific 
disease states has a number of implications for screenings and the future of personalized 
medicine. Similar to the way a patient’s blood pressure and weight is monitored over time, 
tracking changes in an individual’s vaginal flora at different stages of their lifespan (i.e. 
childhood, adolescence, reproductive age, later adulthood) can provide healthcare providers with 
a more comprehensive understanding of a patient’s health (Larsen and Monif, 2001). 
Experiments which examine the bacteria present in a patient’s vaginal microbiome can be scaled 
up and translated to a comprehensive library with bacterial concentrations, species presence, and 
associated patient factors that can be used to monitor an individual’s health and how it is related 
to the vaginal microbiome.  
To reduce the risk of producing false positive results, bacterial biomarkers were considered with 
the potential of producing a binary outcome. Relying on reading a bacterial gradient with an 
array of microbes present in the vaginal microbiome requires further quantification and analysis 
beyond the scope of our device. ​Lactobacillus ​and ​fusobacteria ​species were selected for further 
investigation for possible device integration. ​Lactobacillus ​was selected based on its high 
prevalence in the healthy vaginal microbiome and involvement in regulating the vaginal pH. The 
first steps in this experiment were to determine whether vaginal microbes could be cultivated 
from vaginal swabs on rich media as well as the optimal aerobic environment for growth. 
Fusobacteria ​was selected due to its association with different disease states present in the 
vagina. Experiments were designed to inform the final device design. 
3.2 Methods 
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An in depth literature review was conducted, evaluating the current literature on the vaginal 
microbiome and the present microbes association with disease state, specifically cervical cancer. 
Peer-reviewed articles were selected using the SCU One Search feature on the Santa Clara 
University library website. The findings from this review are summarized in the Table E in 
Appendix A.  
Lactobacillus 
Culturing Vaginal Samples  
Four female students from the Fall 2018 Santa Clara University microbiology class took three 
sterile cotton swabs to procure three vaginal samples. Each vaginal sample was used to inoculate 
a separate tryptic soy agar (TSA) plate. The plates were cultivated in the 37°Celsius incubator for 
48 hours in different aerobic conditions: aerobic, anaerobic, and microaerophilic. To achieve the 
anaerobic growth condition, a “GasPak” culture system was enlisted. In the GasPak jar, the gas 
generator envelope uses a catalyst to combine Oxygen gas with Hydrogen gas, which removes 
O ​2 ​from the sealed container. To create the microaerophilic system, a candle was placed on top of 
the inoculated plates, lit, and then sealed in a jar. The flame from the candle consumes oxygen in 
the sealed chamber and produces carbon dioxide until it is finally extinguished due to insufficient 
oxygen quantity creating a microaerophilic environment. Oxygen test strips were placed in both 
the anaerobic chamber and candle jar system to assess the effectiveness of these chambers in 
producing the desired oxygenation levels. 
After 48 hours, each plate was examined for growth. Colonies that appeared to be distinct 
species based on color and morphology were each analyzed via Gram stain and catalase test. The 
procedures enlisted for both of these tests were taken from Dr. Craig Stephens’ ​Biology 113- 
Microbiology Lab Manual​. To perform the Gram stain, a distinct colony from each separate 
identified strain was picked using a sterile loop and then smeared on a clean glass, microscope 
slide. The colonies were then heat fixed to the slide by passing the slide through the fire three 
times. Following this, the smears were flooded with the primary, crystal violet, stain and were 
left to sit for a minute. Afterwards, the slides were rinsed with deionized water. After the rinse, 
the slides were flooded with the mordant (Gram’s Iodine) and were left to sit for a minute. The 
 
25 
slides were then rinsed again with deionized water. Decolorizer, ethanol, was applied and then 
the slide was left to sit for 15-30 seconds. After another rinse, the slides were flooded with 
counterstain, safranin, and left to sit for 30 seconds. Following this final stain, the slides were 
rinsed again then blotted. Once the slides dried, the staining pattern of the specific species,  the 
general cell morphology, and organization were visualized using a light microscope. 
Isolating Lactobacillus  
Four female microbiology students inoculated selective media with their respective vaginal 
swabs. The medias used were blood agar and Man-Rogosa-Sharpe (MRS); both have been 
reported to be selective for ​Lactobacillus ​(Pendharkar et al. 2013). After 48 hours, any microbes 
that needed to be isolated were restreaked. Those that did not require isolation were analyzed 
using the same procedures as those listed above. Once the colonies that were re-streaked had 
spent 48 hours in the incubator, the analysis procedure were repeated on the resulting isolates.  
Next, the isolates were prepared for 16s ribosomal DNA PCR. First, each colony was suspended 
in 20 microliters of sterile, deionized water. Then, the remaining PCR components were added to 
the mixture. These components include 10 microliters of GoTrg buffer, 1 microliter of dNTP’s, 
0.5 microliters of GF primer, 0.5 microliters of 149z R primer, 0.2 microliters of GoTag, and 17 
more microliters of deionized water. Once this mix was prepared, the 16s ribosomal DNA 
components were amplified via PCR. Following this preparation, these genetic fragments were 
run through a gel. Due to ineffective primers, the gel did not produce accurate results, so this 
process was repeated. With confirmation that the PCR procedure was successful, the isolates’ 
genetic information was be sent to a lab for DNA sequencing. The results are summarized in 
table 8.  
Fusobacterium  
F. Nucleatum ​ ATCC 25586 and ​F. Necrophorum ​ATCC 255386 were streaked for isolation 
using a disposable sterile loop on Anaerobe Systems  Brucella Blood Agar (BRU) and 2
Fusobacterium Selective Agar (FSA). These plates were incubated at 37°Celsius under anaerobic 
2 ​Media produced by Anaerobe Systems is manufactured and packaged in a deoxygenated 
environment. 
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conditions for 48 hours. Anaerobic conditions were met using an anaerobic chamber, with an 
internal environment comprised of 90% N2, 5% CO2, and 5% H2. BRU media was chosen as a 
positive control, supporting the growth of ​Fusobacterium ​ ​spp​. (Brucella Blood Agar- BRU, 
2018). FSA is an enriched selective medium for the isolation and presumptive isolation of 
Fusobacterium ​species, chosen to inform the formulation of CERVIS media discussed in 
Chapter 5 (Fusobacterium Selective Agar- FSA, 2018).  
3.3 Results 
Lactobacillus 
Culturing Vaginal Samples 
Growth was achieved on the TSA plates for 15/16 samples. The observed size and shape of the 
colonies varied between the three respiratory conditions. Colonies grown under anaerobic 
conditions were the smallest and most abundant making them difficult to differentiate, while 
colonies on aerobic plates were dominated by large, circular colonies that we suspected were 
yeast given the aerobic growth conditions. After Gram staining the colonies from the TSA plates, 
it was found that almost every bacteria from these colonies was Gram positive. Additionally, all 
of the cultivated bacteria had a relatively similar morphology: cocci in either chains or clusters 
with positive catalase tests.  
Isolating Lactobacillus  
Limited microbial growth was attained on the MRS plates, and the analysis of colonies from 
these plates was inconsistent, so the data from these plates was discarded. Additionally, many of 
the colonies that grew on the aerobic plates were identified as yeast and our target bacteria 
Lactobacillus ​ is an aerotolerant anaerobe. As a result, the plates grown in the aerobic condition 
were also discarded to help increase selectivity for ​ Lactobacillus. ​ Thus, only the data obtained 
from the analysis of the microbes on the anaerobic blood agar plates was enlisted to determine 
the species each group member cultured. 
All members of the group achieved growth on blood agar media under both aerobic and 
anaerobic conditions. A majority of plates in the anaerobic condition appeared to have a film of 
condensed, small colonies while the colonies on the aerobic plates were larger, and more 
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defined. Though there were differences between vaginal samples, in general there was more 
limited growth on MRS plates under the varying oxygen levels. Although growth was evident in 
both aerobic and anaerobic conditions, we believe that many of the large colonies on our aerobic 
plates, for MRS and blood agar, were yeast. Consequently, the aerobic plates were discarded 
from the data set and not used for subsequent testing and isolation. The remaining anaerobic 
MRS plates were also discarded due to a lack of consistent growth.  
PCR was run for seven of the isolated colonies. None of the sequenced colonies derived from 
subject’s vaginal samples proved to be in the genus ​lactobacillus. ​ ​The results are summarized in 
table 8. ​All identified species are commonly found in the vaginal microbiota, which as you know 
is fairly variable between individuals. The Streptococcus isolates are the closest relatives of 
Lactobacillus ​.  
Table 3: Summary of Findings from Attempt to Isolate Lactobacillus 
Sample Primer 
Edited 
Sequence 
Length (bp) 
Primary Species 
ID (BLAST) 
Primary Species 
ID (SeqMatch) 
Notes 
A 
13;8F.ab
1 
X X X 
13;8Fab.1: 
MIXED 13;1492
R 
744 
Corynebacterium 
aurimucosum 
Corynebacterium 
aurimucosum 
B 
14;8F.ab
1 
708 
Streptococcus 
anginosus 
Streptococcus 
anginosus 
 
14;1492
R 
668 
Streptococcus 
anginosus 
Streptococcus 
anginosus 
C 
15;8F.ab
1 
679 Actinomyces neuii Actinomyces neuii 
 
15;1492 721 Actinomyces neuii Actinomyces neuii 
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R 
D 
16;8F.ab
1 
623 
Enterococcus 
faecalis 
Enterococcus 
faecalis 
 
16;1492
R 
670 
Enterococcus 
faecalis 
Enterococcus 
faecalis 
E 
17;8F.ab
1 
729 
Staphylococcus 
aureus 
Staphylococcus 
aureus 
 
17 
;1492R 
707 
Staphylococcus 
aureus 
Staphylococcus 
aureus 
F 
18;8F.ab
1 
690 
Staphylococcus 
aureus 
Staphylococcus 
aureus 
 
18;1492
R 
767 
Staphylococcus 
aureus 
Staphylococcus 
aureus 
G 
19;8F.ab
1 
695 
Streptococcus 
oralis, pneumoniae 
Streptococcus 
sanguinis 
 
19;1492
R 
725 
Streptococcus 
oralis, sanguinis, 
mitis, pneumoniae 
Streptococcus 
mitis, oralis 
H 
20;8F.ab
1 
X X X 
10;8F.ab1: 
POOR 20;1492
R 
716 
Actinomyces 
urogenitalis 
Actinomyces 
urogenitalis, 
naeslundii, 
howellii, oris 
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Fusobacterium  
Fusobacterium ​ growth was observed on BRU and FSA. Small, white isolated colonies were 
observed after 72 hours. Larger colonies of the same morphology were observed on the BRU 
plate than the FSA plate.  
      
Figure 4: ​F. nucleatum​ Growth on BRU (left) and FSA (right) 
3.4 Next Steps: potential pitfalls and future directions 
The high prevalence of ​lactobacillus ​in the vaginal microbiome eliminated it as a potential 
biomarker for the final device. ​Lactobacillus ​was not isolated from any of the tested subject’s 
vaginal samples, which ​ may suggest a need for improving use of anaerobic culturing to be more 
likely to obtain ​lactobacilli ​.  
F. Nucleatum ​and ​F. Necrophorum ​were determined strong microbial biomarker candidates 
based on their association with cervical cancer and our ability to cultivate these species in the 
lab. The other identified subsystems use ​Fusobacterium ​spp. as the bacterial biomarker of 
interest.  
Microbial biomarkers for high risk HPV warrant investigation. This would allow the device to 
not only have the capabilities of detecting early stage cervical cancer, but also the ability to pick 
up on high risk HPV infections that are strongly linked to the development of cervical cancer 
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(Shannon et al, 2017). Studies show the potential of using other species found in the vaginal 
microbiota as an indicator of HPV infection. ​Sneathia ​ spp. has been described as a possible 
microbiological marker of high risk HPV strains associated with the development of cervical 
cancer and warrants consideration as a secondary biomarker to increase test specificity in future 
device iterations (Lee et al., 2013). 
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CHAPTER 4: Assay Platform  
4.1 Introduction 
In developing the Assay platform, or self-contained design which would house the selective 
growth media described in Chapter 5, two common microbiology techniques were considered: 
the plate and the tube. In developing this self-contained design, the anaerobic growth 
requirement of ​Fusobacterium ​was the most important condition to be met in order to achieve 
bacterial growth. Therefore, the two designs were evaluated based on their ability to maintain 
anaerobic conditions.  
4.2 Methods 
Plate vs. Tube 
The anaerobic environment created using jars described in Section 3.3 was not effective at 
culturing lactobacillus and would not be portable. Therefore, other options were explored to 
culture fusobacterium. The attempted anaerobic environment was created using Ziploc bags, a 
gas pack, and anaerobic indicators. The gas pack would effectively remove oxygen from the 
environment once the bag was opened or if oxygen leaked into the system. The anaerobic 
indicators were used to determine if anaerobic conditions were maintained. Plates were streaked 
with inoculated fusobacterium cultures and immediately placed into the anaerobic environment, 
keeping air exposure to a minimum.  
Swab Selection 
To determine the swab type that resulted in the least oxygen exposure a series of five different 
swabs without bacterial samples were tested in parallel experiments. In order to conduct the 
experiment, anaerobic transport media tubes were used, which include a chemical resazurin, 
which reacts with oxygen creating a color change. Each swab was submerged into the media tube 
and dipped then removed from the media tube. The swabs tested included: the Cervex brush, the 
cervical spatula, the cotton swab, the polyester swab, and the bristle brush. During testing each 
tube was exposed to oxygen for no more than 15 seconds, the test was performed at room 
temperature, and the tubes were checked after 24 and 48 hours.  
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Swab Mechanism  
After the swab was selected the same test was repeated with this swab to further verify which 
swabbing mechanism would result in the least amount of oxygen entering the system. The swab 
was first submerged into the anaerobic transport media tube containing resazurin. In parallel, the 
same swab was dipped and then removed from the media tube. The results of both trials were 
compared. 
4.3 Results 
Plate vs. Tube  
After attempting to create an anaerobic environment with Ziploc bags, the enclosure remained 
anaerobic for the first 24 hours, but no bacterial growth was observed. Furthermore, by 72 hours 
the anaerobic indicators changed color from pink to purple showing that the environment within 
the Ziploc bags was no longer anaerobic, as shown in Figure 5. No growth was observed. It was 
concluded that by the 72 hour mark the gas packs were no longer actively removing oxygen and 
that anaerobic conditions were no longer maintained. Overall, anaerobic conditions necessary to 
grow fusobacterium were not achieved.  
Sandwich Bag + Quart Bag Freezer Bag + Sandwich Bag Double Freezer Bag 
   
Figure 5: Anaerobic Systems Experiment after 72 hours 
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Following the unsuccessful results creating an anaerobic environment to culture ​Fusobacterium ​, 
attempts to culture the bacteria in the anaerobic hood began. Successful growth on plates was 
then achieved as shown in Figure 3. However, it was concluded that it would be difficult to 
create an entirely anaerobic environment using the plates, as oxygen exposure occurred across 
the entire surface area of the plate, penetrating into the media. Therefore the tube design was 
pursued per results which are discussed below.  
Swabbing Mechanism 
Table 4: Results of Swab Submersion Experiments 
 t=0 48 hours 72 hours 
Cervex Brush 
   
Cotton Swab 
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Bristle Brush 
 
  
Polyester Swab 
 
 
 
Cervical Spatula 
 
  
 
Table 4 above summarizes the results of the swab selection experiment. As indicated by the color 
change, submerging the swab in the tube was the best method to maintain anaerobic conditions. 
In conducting this experiment, the sizes of the cervex brush and cervical spatula were too big to 
be inserted into the tube, and needed to be cut to fit, making their size an issue. The cotton swab 
was also eliminated due to the toxic nature of the wooden handle which could prevent bacterial 
growth. Between the polyester swab and bristle brush, research supported that the bristle brush 
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collects a better sample than the polyester swab, so the bristle brush was selected. Table 12 
below summarizes this selection.  
Table 5: Final Swab Selection 
 Size Toxicity  Collection 
Cervex Brush  ✓ ✓ 
Cervical Spatula  ✓ ✓ 
Cotton Swab ✓  ✓ 
Polyester Swab ✓ ✓  
Bristle Brush ✓ ✓ ✓ 
 
Table 13 shows the results of verifying the submersion swabbing mechanism as the best method 
to maintain anaerobic conditions. As shown by the images below, leaving the bristle brush 
submerged in the media resulted in the least oxygen exposure, indicated by the pink color change 
isolated to the top of the tube.  
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Figure 6: Sampling Mechanism Oxygen Exposure 
These experiments​ ​informed the final design prototype. The design was decided to be a tube with 
semi-solid media to maintain anaerobic conditions and keep the swab submerged to create a 
self-contained test.  
4.4 Next Steps: Potential Pitfalls and Future Directions 
After deciding to move forward with the tube design, bacterial growth had yet to be observed. 
Given the results from the anaerobic transport media, it was reasonably concluded that 
conditions necessary for growth could be achieved as the bottom 70% of the tube remained 
anaerobic. 
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CHAPTER 5: Growth Media 
5.1 Introduction 
As noted in the introduction, the test for ​fusobacterium ​growth requires a selective media and an 
anaerobic environment. The media developed fulfills these criteria through the methods listed 
below. 
5.2 Methods 
Lab procedures focused on growing ​fusobacterium ​on both selective and non-selective solid 
media plates incubated at 37°C. Both BRU and FSA contain blood and therefore appear dark red. 
While this coloring actually increases the ease of growth observation on solid media plates, it 
makes growth observation very difficult in media tubes. Therefore, a novel media, CERVIS 1.0 
was developed to include the selectivity of FSA without incorporating blood. FSA contains three 
antibiotics that select for fusobacterium: vancomycin, neomycin, and josamycin (Morgenstein, 
Citron, & Finegold, 1981). Thus, CERVIS 1.0 contained all three of these antibiotics to maintain 
the selectivity. To provide a nutrient rich media base, porcine Brain Heart Infusion (BHI) broth 
was also added to the media. Porcine was selected over bovine or other options for ease of future 
use. Some countries have laws against the transport of bovine material across borders for disease 
prevention and protection, so porcine material is a safer choice. BHI was selected primarily 
because it is transparent and prior research suggests that fusobacterium can grow optimally on 
this media (Han, 2006). The complete list of ingredients in the media is listed in Appendix 
Figure A. 
In order to test the CERVIS 1.0, pure ​fusobacteria ​ cultures of F. ​nucleatum ​ and F. ​necrophorum 
were plated and incubated at 37°C until colony formation was observed. Approximately two 
colonies of each strain were taken from the plated cultures using a bristle brush, which was then 
used to inoculate the media. The inoculated sample tubes were then incubated at 37°C outside of 
the anaerobic chamber and growth was monitored over a period of 72 hours. 
5.3 Results 
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The non-selective media, Blood Brucella Agar (BRU) successfully grew ​Fusobacterium ​ cultures 
in the anaerobic chamber. The selective media, Fusobacterium Selective Agar (FSA), developed 
by Anaerobe Systems was also successful in growing ​Fusobacterium ​colonies, but the observed 
colonies were much smaller. 
The first iteration of the CERVIS media, CERVIS 1.0, was a major milestone for the project’s 
success. The media supported the growth of pure ​fusobacteria ​ cultures of F. ​nucleatum ​ and F. 
necrophorum ​ in tubes incubated at 37°C both inside and outside the anaerobic hood.  This 
proved that an obligate anaerobe could be grown in CERVIS media outside of a contained 
anaerobic chamber and showed that the media successfully maintained anaerobic conditions. 
Additionally, this proved that the media contained enough nutrients to support growth. However, 
bacterial growth was difficult to distinguish from other artifacts or air bubbles within the media, 
as shown in Figure 7.  
 
Figure 7: Fusobacteria Growth in CERVIS 1.0 Media 
The results of the tests using CERVIS 1.0 were difficult to interpret. Additionally, there was no 
confirmation that the organisms growing in the tube really were ​Fusobacterium ​ spp. In order to 
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make a more accurate test where growth was easy to visualize, a secondary differential test for 
the presence of fusobacteria was deemed necessary. 
CERVIS 2.0 was developed to address the limitations of CERVIS 1.0. To identify growth more 
easily and with better accuracy, components of a secondary test were implemented in the media. 
The secondary test, modeled after Triple Sugar Iron (TSI) tubes, confirms that any growth seen 
is actually fusobacterium. If enough cysteine is present in the media, fusobacterium can produce 
dihydrogen sulfide  (Basic et al., 2015). This byproduct can then react with ammoniumH S)( 2  
iron (iii) sulfate hexahydrate, which acts as an indicator and turns black when isSH2 SH2  
present. Thus, the presence of fusobacterium, the media will turn a dark black color, in Figure 8 
below, that is significantly different from the control golden color of the media in the absence of 
fusobacterium. L-cysteine also acts as an oxygen reducing agent, eliminating the need for DTT 
in CERVIS 2.0. resazurin was removed because the anaerobic conditions of the media were 
already  tested and proved and adding this color change was thought to interfere with the color 
change from the secondary test. Additionally, magnesium sulfate heptahydrate was added to help 
solidify the Gelrite to maintain the semisolid consistency (Basic et al., 2017). 
The same experiments outlined in the CERVIS 1.0 media above were performed with CERVIS 
2.0 media to measure and compare its functionality. The results shown in Figure 8 display the 
growth of F. ​nucleatum ​ (middle) and F. ​necrophorum ​ (right) in CERVIS 2.0 media compared 
against the control, with no bacterial sample introduced, seen on the left.  
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Figure 8: ​Fusobacterium ​Growth in CERVIS 2.0 Media 
As depicted, the media changed from a transparent, golden color, seen in the control sample, to a 
murky black in both strains. This color change shows the product of the secondary test, which 
confirms the presence of fusobacterium growth in the tube. Again, this test was performed 
outside of the anaerobic chamber, confirming that the media maintained anaerobic conditions 
sufficient for fusobacterium growth. To confirm that no other bacteria from a vaginal swab 
would cause this color change, five members of the team performed vaginal swabs and inserted 
them into CERVIS 2.0 media, following the procedures outlined in Section 3.2. The results of 
this experiment are shown in Figure 9.  
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Figure 9: Vaginal Swabs in CERVIS 2.0 Media 
While each tube with a vaginal swab looks slightly cloudier than the control tube, there is no 
color change, proving that no other presumably relevant bacteria would cause the color change 
indicating the results of the test. 
5.4 Next Steps: Potential Pitfalls and Future Directions 
CERVIS 2.0 was successful in growing fusobacterium selectively, but the sensitivity of the 
media is not yet known. Experimental plans to begin estimating the sensitivity of the media are 
outlined in Section 6.2.1. Additionally, the color change in the presence of fusobacteria was only 
observed at 37°C. At room temperature, some growth was observed but the media remained a 
golden color. This indicated the need for some form of incubation, which must be considered for 
the final device design and implementation.  
It is not yet understood what other microbial species in the vaginal microbiome produce 
hydrogen sulfate as a byproduct and will in turn, invoke the reaction in the presence of 
L-cysteine to blacken the CERVIS media in the vial. Further testing is necessary to better 
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understand the validity of CERVIS as a viable screening method for early stage cervical cancer 
and what the risk of false positives is due to other bacteria that can grow in CERVIS media and 
invoke the reaction. To test this, samples from human cervical cancer patients must be collected 
and tested. 
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CHAPTER 6: Conclusion & Future Directions  
6.1 Prototype  
Over the course of this project, a biomarker that has the potential to indicate the presence of 
cervical cancer has been identified using emerging research on the vaginal microbiome, and a 
novel screening test capable of selectively detecting for this species of bacteria from a patient 
sample was designed. The scope of the project focused on the development of this prototype 
through the creation of a selective media that incorporated the antibiotics from FSA media and 
maintained anaerobic conditions through the use of a semi-solid media with oxygen scavengers. 
The physical form of the assay incorporated a patient sample through the use of a vaginal swab 
taken with a bristle brush. This sample applicator was selected from a group of five applicators 
tested on the criteria of size, toxicity, and sample collection. The screening method is minimally 
invasive as it only requires a single self-administered vaginal swab. The test is self contained as 
the swab is inserted directly into the media and sealed with a cap. These characteristics of the 
screening method help to minimize the need for clinically trained personnel to be present to 
conduct the test or analyze the result; hopefully, alleviating the need for women to seek out 
traditional clinical settings in order to gain access to preventative care. The final iteration of the 
proposed design of the screening test currently costs less than $5 to manufacture, with the 
hungate tube and cap being the most costly items. Reference Figure A in the Appendix for a 
complete cost analysis.  
 
Figure 10: CERVIS Prototype  
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6.2 Sensitivity  
To better understand the correlation of the bacterial samples from our initial tests compared to 
the vaginal microbiome of a diseased patient, calculated estimations were made to investigate the 
sensitivity of the CERVIS 2.0 prototype. It is known that 17% of the vaginal microbiome is 
composed of fusobacterium in the case of Cervical Cancer ( ​Audirac-Chalifour et al., 2016) ​. 
Bartlett et al., reports an average of 10 ​9 ​anaerobic bacteria in the average vaginal microbiome 
( ​Bartlett, 1977).  
Quantification of Fusobacterium in the Vaginal Microbiome of a Cervical Cancer Patient: 
7% of  10 170, 00, 001 9 =  0 0  
Mitra et al., notes the average bacterial load using a cytology (bristle) brush is 6.41. This value is 
reported on a log base 10 scale. Therefore, assuming that the bacteria taken up by one sample 
using the CERVIS 2.0 sampling device, 2570395 bacteria are collected by one swab.  
Quantification of Fusobacterium in one swab from a Cervical Cancer Patient: 
 17% of 2,570,395 = 436,967 
It is noted that these calculations are rough estimates, as the vaginal microbiome is highly 
variable between individuals due to factors including sexual activity, menarche, menses, age, 
pregnancy, infection, and birth control (Huang et al., 2014).  
Next, the estimated number of fusobacterium in the diseased vaginal microbiome was compared 
to the colonies taken up by the swab during experimentation. It is estimated that one colony 
contains an average of 10 ​7  ​bacteria. For each plate of fusobacterium ( ​F. necrophorum and F. 
nucleatum ​) 2 colonies were collected using the cytology (bristle) brush. Under this assumption 
20,000,000 bacteria of pure ​fusobacterium ​spp. respectively were delivered into each tube.  
In conclusion, 436,967 bacteria (estimated patient sample) < 20,000,000 bacteria (estimated 
experimental sample). Thus, these calculations are insufficient in correlating the vaginal 
microbiome to colonies on a plate. Further sensitivity testing is required.  
6.2.2 Preliminary Sensitivity Experiments 
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To further estimate the sensitivity of the device, an experiment was designed under aerobic 
conditions to estimate the threshold of bacteria needed to cause the color change in CERVIS 2.0 
media. The experiment is outlined as follows: 
Using BHI media, create a suspension of cells from a colony of ​ F. necrophorum ​ and ​F. 
nucleatum. ​ BHI broth from Anaerobe Systems is maintained anaerobically, which is why it was 
chosen as the solvent over saline typical of a dilution series. These cultures were used to roughly 
estimate cell density.  
Serial dilutions were prepared using the cultures. To prepare the first dilution, add 1 mL of 
culture to 99 mL BHI ( dilution). Next, 1 mL of the  dilution should be added to01 −2 01 −2  
another 99 mL BHI to generate a  dilution. At this point, three further dilutions should be01 −4  
prepared ( to ) adding new samples of ​f. Nucleatum and f. necrophorum ​ to 4.5 ml BHI.01 −5 01 −7  
After completing the dilution series, a bristle brush should be used to take a sample from each 
dilution. The brushes should be inserted directly into the CERVIS 2.0 media and the tubes 
immediately resealed to maintain anaerobicity.  
This experiment was not conducted due to unforeseen laboratory challenges. At the time of 
scheduled experimentation, both control strains of ​fusobacterium ​previously plated on FSA were 
dried, and well-defined colonies were not collectable by bristle brush. Thus, the starter culture 
could not be made. Moving forward, sensitivity testing is necessary to validate the integrity of 
the CERVIS 2.0 device. 
6.3 Device Implementation 
Human Subjects Research 
There currently lacks adequate data to confirm that the bacteria introduced by a colony from a 
pure culture represents the vaginal microbiome of a disease state. In order to clinically scale up 
the device, a partnership with a research hospital is required to confirm device sensitivity and 
specificity. Following the required protocols for human subjects testing, CERVIS 2.0 will be 
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tested with patient samples from representative populations of the following categories: HPV 
negative, HPV positive, intraepithelial lesions, and cervical cancer. 
Clinical Trial in the United States 
The results from the human subjects research testing will inform a clinical trial conducted within 
the United States. To properly conduct a clinical trial, the IRB protocol and FDA 510-k filing 
will be completed. The prototype will be classified as an in vitro diagnostic Medical Device for 
self-testing, because it is intended by the manufacturer for use by lay persons and its 
noninvasive nature. Additionally, since other medically established means of diagnosis of 
cervical cancer exist, we will not need to file for an Investigational Device Exemption (IDE).  
Sustainable Partnership with Aga Khan University  
The clinical trial will be repeated in Kenya to guarantee the results are replicable within the 
target population. Variations in the microbiome are dependent partially on the individual’s 
environment, and this trial will ensure that the microbiome is consistent enough that 
fusobacterium is an appropriate biomarker in this context. 
Pilot Test within Target Community  
Upon test validation, the device will be pilot tested in a community near Nairobi, Kenya in a 
manner that is culturally appropriate. This may be completed by using the device initially in a 
community setting, screening a number of women at a location they regularly frequent, similar to 
a blood drive. Results from this test will inform how the device is deployed on a larger scale. 
6.3.1 Supplemental to Current Screening Tests 
Per current research, the ​Fusobacterium ​strains of interest are only present in the vaginal 
microbiome of individuals with precancer and cancer. Although our device will never replace the 
current diagnostic standard, our device is a less-invasive and lower-costing alternative that is 
indicative of serious disease. For this reason, it is necessary to have a standard for referring 
women who test positive to seek further screening and subsequent treatment. The methods for 
further screening are outlined in Section 1.2, and the educational component included in the 
CERVIS implementation strategy will contain relevant information about these methods and 
available treatment options. Additionally, the targeted areas for pilot testing must have the means 
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to access such subsequent methods. As device deployment is scaled up, methods of transporting 
women from rural areas to more developed areas with a greater capacity for medical care must 
be explored. 
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CHAPTER 7: Engineering Standards 
7.1 Manufacturability 
Anaerobe Systems is the producer of the world’s only true pre-reduced anaerobically sterilized 
(PRAS) culture media poured and packaged under anaerobic conditions ​ (Anaerobic Chambers & 
Culture Media Manufacturer, 2018 ​). This company is currently the independent manufacturer of 
CERVIS media. According to Anaerobe Systems product quality and development manager, it 
takes between 4 – 6 different people to produce one liter of media, all with varying hourly pay 
rates. The manufacturing procedure is outlined in the following paragraphs. 
The Anaerobe Systems production manager first schedules the manufacturing and determines 
who will make the media. He/She also orders all necessary components and ensures the correct 
equipment is being used. Next, the mixing technician makes the media and starts the sterilization 
process. Once the media is sterilized, another technician adds any heat labile components like the 
antibiotics. Only a few people at Anaerobe Systems are authorized to do this since it takes a 
skilled person to perform this procedure correctly without contaminating or harming the media.  
Next, a different production technician hand pours the media in pre-sterilized tubes. They need to 
be pre-sterilized beforehand since heat-labile components are added after the primary media is 
sterilized. They cannot be sterilized in the tubes since that will destroy the antibiotics. This 
increases the cost since a person needs to hand pour the media instead of just placing it on the 
automatic tube pouring machine. That machine can only be used for media that can be sterilized 
in the tube. The machine also pours tubes faster than a technician can. All the media is made 
within larger anaerobic chambers in production, which have their own electrical expenses and 
nitrogen gas consumption.  
Once the tubes are poured, they need to be labeled and packaged in foil filled with nitrogen gas 
and sealed. Some cost considerations include electricity, including the AC unit to maintain the 
appropriate room conditions and the lights so employees can see. Additionally, autoclaves and a 
boiler are used to make the steam for sterilization.  
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Once the media goes to quality control for approval, a quality control technician conducts 
sterility and performance tests on the media. This requires specialized skills and equipment 
including an anaerobic chamber, incubators, and other general laboratory equipment like loops 
and saline blanks. All necessary organisms are preemptively cultured on a general media like 
Brucella blood agar (BRU). This machinery requires electricity to operate and the anaerobic 
chamber requires expensive tri-mix gas. Once all the testing is completed, the quality control 
manager approves and passes all media.  
7.2 Ethics 
The primary ethics question that arose from this project was: ​Is it ethical for a team from the 
developed world with little first-hand knowledge of the cultural practices in the target location to 
develop an alternative screening method and, if so, on what basis?  
 Developing and implementing a low-cost, minimally-invasive screening method that is 
culturally relevant will benefit the common good and improve social justice because it will limit 
the the need for more invasive procedures, increase the chances for successful treatment, and will 
reduce incidence and mortality rates for women living in low- and middle-income countries. 
There are a variety of stakeholders that warrant consideration when addressing this question. The 
most important are the women living in Kenya who because of CERVIS will have a lesser 
chance at contracting late stage cervical cancer compared to women in other similar sub-Saharan 
countries. Additionally, community health workers, doctors, and volunteers involved in the care, 
delivery, and education concerning our device have a stake in our project. Our team from Santa 
Clara University, including students from the departments of bioengineering and public health 
science, and our advisors from biology, bioengineering, and public health science all have a 
stake because the researchers care about designing the device to work as intended and cause the 
most benefit and least amount of harm to our target community.  
On a greater scale, the members of the cervical cancer research community including researchers 
and doctors from around the world have a stake because our device has the potential to reduce 
the burden of disease significantly, especially for individuals in previously unreachable contexts. 
Since the bacteria our device detects is indicative of other disease states in other microbiomes, 
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this device has the potential to screen for other diseases beyond cervical cancer. This extends the 
stakeholders beyond the cervical cancer community to dentists and other oncologists and 
researchers. The employees at Anaerobe Systems, a corporate partner helping manufacture 
CERVIS, hold a stake in terms of the viability of the product because they are interested in 
expanding their market (primarily microbiology researchers working with anaerobic bacteria) to 
helping people in the developing world. Society is always a stakeholder.  
7.3 Other Emerging Work  
Intellectual Ventures  
A research team led by investigators from the National Institutes of Health (NIH) and Global 
Good has developed a computer algorithm that can analyze digital images of a woman’s cervix 
and accurately identify precancerous changes that require medical attention. This artificial 
intelligence (AI) approach, called automated visual evaluation, has the potential to revolutionize 
cervical cancer screening, particularly in low-resource settings. This new technology could 
dramatically improve the screening capabilities of clinics in low-resource settings, as it requires 
minimal training, which makes it ideal for contexts with limited resources. However, many 
cultural barriers exist that prevent women from seeking out preventative care, and many women 
only go to the clinic if they are experiencing symptoms or are pregnant. Therefore, one limitation 
of this innovation is that it requires a clinical setting ( ​AI approach outperformed human experts 
in identifying cervical precancer, 2019) ​.  
Unitaid Projects  
From May 2018 to September 2018, Unitaid collected submissions  for projects seeking to help 
eliminate the incidence of cervical cancer in low and middle income countries. Unitaid is aware 
of the need for expanded access to screening in order to reduce the incidents of cervical cancer 
deaths in these settings. Currently, Unitaid is developing two grants related to cervical cancer 
screening and treatment, and at this time both have not been published. The projects are moving 
into the final development stages and further information should be available in coming weeks 
(Preventing Deaths from Cervical Cancer, 2018).  
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7.4 Engineering Standards & Realistic Constraints 
Economics, manufacturability, cultural impact, and health and safety are the engineering 
standards affecting device design. 
Economics 
Pilot testing is intended to take place in Nairobi, Kenya and for this reason, the economic 
landscape of Kenya must be evaluated. The low cost of CERVIS is aimed to address this 
challenge, enabling women of all socioeconomic backgrounds the ability to be screened for 
cervical cancer (See Appendix). 
Manufacturability 
The device is currently manufactured by Anaerobe Systems in Morgan Hill, CA. For long term               
scale-up and sustainability, manufacturing options in Kenya warrant consideration.  
Cultural Impact 
Religion plays an important role in the life of most Kenyans, and the concept of virginity is 
highly valued by both Christians and Muslims, the two most predominant faiths practiced in 
Kenya (Spronk, 2005). In earlier iterations of our device, team CERVIS explored tampons and 
menstrual cups as a means to collect blood samples from women that could be used to screen for 
cervical cancer. However, after talking to several nurses working in sub-Saharan Africa, it 
became clear that these items are not typically used due to a stigma that a “broken” hymen 
equates to a loss in virginity. Despite having no identifiable role in the woman’s body, the hymen 
retains significant religious and moral value in Kenyan society (Odongo, 2015). The uptake of 
earlier detection methods was limited by the Kenyan belief that hymenal integrity signifies 
virginity, and women would not use earlier collection methods because of the fear of tearing the 
hymen.  
Our current prototype requires a woman to self-swab her vagina using a small, soft bristle brush. 
Although this is less-invasive than a tampon, a woman using our device may have similar fears 
about virginity after inserting the swab. To address these fears, an educational component 
designed by nurses and educators working in the field to help women understand their anatomy, 
the benefits of screening, and how to use our device effectively would be necessary. A hymen 
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can be “broken” through sex, by using a tampon or a menstrual cup, doing sports, or visiting a 
gynecologist, and misunderstanding this information poses challenges in implementing cervical 
cancer screening interventions (Sayer, 2018).  
Health and Safety 
Health and safety is the most important factor under consideration. To ensure this goal is 
maintained and monitored, an educational program should be co-developed by educators, 
volunteers, and healthcare workers on the ground that helps to explain a woman’s anatomy and 
the importance of screening for cervical cancer in addition to creating an alternative low-cost 
screening method and deploying it in Kenya. A plan to increase access to subsequent screening 
and treatment options for women who test positive after using CERVIS must also be put into 
place. 
Additionally, once a vaginal swab is administered and introduced to the media, CERVIS 2.0 
becomes a biohazard that needs to be disposed of properly to maintain the health and safety of 
the community. Establishing clear, well-defined policies to ensure proper disposal must be put in 
place prior to device implementation.   
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APPENDICES  
Table A: Summary of Goals, Objectives, and Expected Results 
Goals Objectives Expected Results 
Create an alternative 
screening method for cervical 
cancer  
Develop a working prototype  A final sketch of a proposed 
device  
Device must not require a 
clinical setting 
Develop a test that is easy to 
use without laboratory 
equipment or medical 
expertise 
The final device can be 
self-administered as an 
at-home test 
Device must be 
self-contained 
Develop a handheld device 
that does not contain any 
loose components 
Device will resemble a 
pregnancy test 
Device must be low-cost Create a device for less than 
existing methods  
Cost will depend on final 
biomarker selection 
Device must produce a binary 
output 
Create an output that is easily 
interpreted in the field (+/-) 
Device produces a binary 
output when introduced to a 
biomarker  
Device must be deployable in 
low- and middle-income 
countries  
Create sustainable 
partnerships with healthcare 
workers in the field 
Partnerships formed 
throughout the year will be 
professional and provide 
information through 
interviews to inform the 
cultural relevance of the 
project 
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Table B: Funding Received 
Funding Received School of Engineering $2000 
 Xilinx Grant $500 
 Total Received  $2500 
 
Table C: CERVIS Expenditures 
Product 
Description 
Company/ 
Provider 
Product 
Number 
Unit Cost Total Cost Date 
Ordered 
FSA media Anaerobic 
Systems 
353136 9.18 45.9 1/11/19 
Anaerobic 
pouches 
Biomerieux 46968 73.93 128.01 1/17/19 
Anaerobic 
Indicator 
Biomerieux 46971 1.28 42.73 1/21/19 
Fusobacterium 
nucleatum 
subsp. 
ATCC 25586 133.26 133.26 1/29/19 
Anaerobic 
Transport 
Medium 
Anaerobic 
Systems 
3381118 20.42 20.42 1/31/19 
FSA media Anaerobic 
Systems 
353136 9.18 45.9 2/4/19 
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Fusobacterium 
nucleatum 
subsp. 
ATCC 25586 133.26 133.26 2/12/19 
Puritan 
Cytology 
Bristle 
Brushes 
Marketplace 
Direct 
252199 0.59 58.91 2/12/19 
Anaerobic 
Chamber Gas 
Praxair 88404127 640.24 640.24 4/8/19 
Total Spent 1,230.27  
 
Table D: 2018-2020 Academic Timeline for CERVIS  
 Fall Quarter Winter Quarter Spring Quarter 
Week 1 First meeting after 
summer recess with 
Primary Advisor Dr. 
Prashanth Asuri  
Partnership formed 
between BIOE students 
and EWH students 
Working in Dr. Stephens 
microbiology lab is 
confirmed 
Fusobacterium ​is selected 
as the bacterial biomarker 
of interest 
EWH & BIOE students 
draft preliminary 
experiments for winter 
quarter lab work 
CERVIS1.0 results 
collected and analyzed 
 
Second collaborative 
effort with Anaerobe 
Systems to design 
CERVIS2.0  
Week 2 First meeting with all 
team members- 
Accepted to present at CERVIS 2.0Media 
Tested with Pure Strains 
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brainstorming session on 
prospective analytes and 
biomarkers 
Unite for Sight Conference  
Environmental Health and 
Safety form approved for 
Stephens lab 
Initial materials order 
placed  
Registration confirmed for 
Senior Design Conference 
presentation 
of ​Fusobacteria ​spp. and 
samples from female 
group members  
Short presentation 
delivered to advisory 
board members 
(Bioinnovation & 
Design) 
Week 3  Second Frugal Innovation 
workshop with Gregory 
Theyel 
Final Frugal Innovation 
workshop with Gregory 
Theyel  
Unite for Sight Global 
Health & Innovation 
Conference 
Week 4 Crashing brainstorming 
session- bacteria 
biomarker idea comes to 
fruition 
Anaerobicity experiments 
run in lab; attempt to grow 
fusobacterium ​in a 
micro-aerobic environment  
GHTC Paper submitted 
for review 
Week 5 Dr. Craig Stephens joins 
the team- preliminary 
budget/list of material 
submitted to School of 
Engineering 
CERVIS team runs the 
Kaiser Permanente San 
Francisco half marathon 
Colonies grown under 
different aerobic conditions 
analyzed using 16s 
Sensitivity Testing 
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ribosomal RNA sequencing 
Meeting with Dr. Ruscetti 
alters project trajectory- 
refocused on device design  
Week 6 First Frugal Innovation 
workshop with Gregory 
Theyel  
Conversation with Lata 
Mukundan from CCSA for 
a discussion on the 
therapeutic potential of the 
human microbiome  
Dr. Ruscetti guided a 
training session to work in 
the anaerobic hood 
Control culture of ​F. 
nucleatum ​ was plated and 
streaked for isolation on 
FSA under anaerobic 
conditions 
Meeting with Mike Cox 
and Hiram Lonzo at 
Anaerobe Systems inspires 
device prototype 
Senior Design 
Conference 
Week 7 Preliminary experiments 
run in attempt to 
cultivate lactobacillus 
IEEE Conference 
Presentation at San Jose 
State University 
Finalize Thesis Rough 
Draft 
Week 8   Coordinate Next Steps 
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for Project Continuation 
Week 9 EWH students begin 
working on abstract for 
GHTC  
 Submit Thesis to 
Bioengineering Adviser 
for Revisions 
Week 
10 
Group meeting with all 
advisors, EWH, and 
BIOE students; recess 
until post winter break 
Experimental lab work in 
the anaerobic hood using 
CERVIS 1.0 Media 
Final Thesis Submission 
 
Table E: Information about Vaginal Microbiota 
Species Gram 
(-/+) 
Fermentatio
n products 
Morphology O2 
tolerance 
Other important 
characteristics 
Source: 
L. 
crispatus 
+ H2O2 (can 
be used as 
antimicrobia
l agent) 
Lactic acid 
(lower 
environment
al pH- 
another 
antimicrobia
l attack) 
Rods Obligate 
anaerobe- 
aerotolera
nt 
-Approx 60% 
healthy vaginal 
biome 
-produce 
antibiotic 
products that 
target E.coli and 
Candida 
https://ww
w.ncbi.nl
m.nih.gov/
pmc/articl
es/PMC49
85617/ 
 
G. 
vaginalis 
gram 
variabl
e 
G. vaginalis 
ferments a 
wide variety 
Coccobacilli 
(Short rods)  
Nonmotile  
Facultativ
e 
anaerobes 
-Is the main 
cause of 
Bacterial 
https://ww
w.ncbi.nl
m.nih.gov/
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of 
carbohydrat
es, 
producing 
acetic acid 
as an end 
product. ​G. 
vaginalis 
does not 
reduce 
nitrate or 
hydrolyze 
urea.  
 
Negative 
catalase test 
Vaginosis 
-it has been 
found in 15% to 
69% of women 
without signs or 
symptoms of 
vaginal infection 
- ​G. vaginalis 
can be sexually 
transmitted 
-Its role in 
pathogenesis 
may be through 
altering the 
microbial 
environment due 
to RBC  lysis 
releasing iron 
metabolites or 
through altering 
the host 
response 
pubmed/6
389437 
 
https://ww
w.science
direct.com
/topics/me
dicine-and
-dentistry/
gardnerell
a-vaginali
s  
L. Iners + 
Variab
le  
Catalase 
negative  
lactic acid 
bacteria 
group (i.e. 
they convert 
Rods Facultativ
e 
anaerobe 
  
https://ae
m.asm.org
/content/a
em/early/2
016/09/26/
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sugars to 
lactic acid). 
AEM.023
85-16.full.
pdf  
https://ww
w.cell.co
m/trends/
microbiol
ogy/pdf/S
0966-842
X(16)301
81-0.pdf  
L. Gasseri + Catalase 
negative 
Rods anaerobic More common 
in the colon- not 
super worried 
about this one 
https://mic
robewiki.k
enyon.edu
/index.php
/Lactobaci
llus_gasse
ri  
L. 
Jensenii 
+ Catalase 
negative 
Rods anaerobic It is one of the 
predominant 
species (along 
with 
Lactobacillus 
crispatus ​) found 
in the female 
lower genital 
tract 
https://mic
robewiki.k
enyon.edu
/index.php
/Lactobaci
llus_jense
nii  
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S. 
Agalactia
e 
+ Catalase 
negative 
Lactic acid 
Spherical  Microaer
ophilic 
- ​Causes 
meningitis in 
neonates and 
elderly  
- Occasionally 
colonizes female 
reproductive 
tract 
- Increase risk 
for premature 
rupture of 
membranes and 
transmission of 
infection to 
child 
https://ww
w.science
direct.com
/sdfe/pdf/d
ownload/e
id/3-s2.0-
B9781437
72702900
1215/first-
page-pdf 
https://ww
w.sigmaal
drich.com/
technical-
documents
/articles/a
nalytix/str
eptococci-
overview.
html  
L. 
Acidophil
us 
 undergoes 
fermentatio
n only 
 Anaerobi
c  
 https://jcm
.asm.org/c
ontent/45/
9/3145  
F. 
Necropho
rum 
- H2S Rods Anaerobi
c 
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F. 
Nucleatu
m 
- H2S Rods Anaerobi
c  
  
 
 
 
4/8/19 at 09:44:39.04 Page: 1 
Anaerobe Systems 
Bill of Materials Report 
As of Apr 8, 2019 
Filter Criteria includes: 1) Item ID's from WP-MED-723 to WP-MED-723. Report order is by Item ID. Report is printed in Detail format with with shortened 
descriptions. 
Item ID 
W P-MED-723 
. RM-0525 
. RM-3480 
. RM-0930 
. RM-1580 
. RM-3350 
. RM-2020 
. RM-1320 
. RM-1720 
. RM-0152 
WP-M ED-723 Total 
Item Descript ion 
CERVIS MEDIUM 
BRAIN HEART INFUSION- PORCINE 
YEAST EXTRACT TECH GRADE 
CYSTE INE-SIGMA 
JOSAMYC IN 
VANCOMYC IN 
NEOMYC IN TRISULFATE 
GELLAN GUM 
MAGNESIUM SULFATE HEPTAHY D 
AMMON IUM IRON II SULFATE HEXA 
Qty Needed Qty on Hand Est Cost 
37.00 873 .00 12.95 
5.00 1791 .76 0.70 
1.00 2327 .77 0.60 
0.00 0.21 3.99 
0.01 31.55 0.44 
0.16 43 .23 0.31 
4.00 4248.00 1.44 
0.10 1465.45 0.01 
0.20 2.00 
20.44 
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Figure A: Anaerobe Systems Bill of Materials 
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Anaerobe Systems 
Bill of Materials Report 
As of Apr 8, 2019 
Page: 1 
Filter Criteria includes: 1) Item ID's from WP-PACK-723 to WP-PACK-723. Report order is by Item ID. Report is printed in Detail format with with shortened 
descriptions. 
Item ID Item Description Qty Needed Qty on Hand Est Cost 
W P-PACK -723 CERVIS MEDIUM 
. RM-2415 POUCH ES ANA EROBIC 6 x 7.25 1.00 34664 .00 0.21 
. W P-EA-723 CERVIS MEDIUM 10.00 
W P-MED-723 CERVIS MEDIUM 0.07 
... RM-0525 BRAIN HEART INFUSION-PORC INE 2.59 873 .00 0.91 
... RM-3480 YEAST EXTRACT TECH GRADE 0.35 1791 .76 0.05 
... RM-0930 CYST EINE-SIGMA 0.07 2327 .77 0.04 
... RM-1580 JOSA MYCIN 0.00 0.21 0.28 
.. RM-3350 VANCOM YCIN 0.00 31.55 0.03 
... RM-2020 NEOMYC IN TRISULFATE 0.01 43.23 0.02 
. .. RM-1320 GELLAN GUM 0.28 4248 .00 0.10 
... RM-1720 MAGNESIUM SULFATE HEPTAHY D 0.01 1465.45 0.00 
... RM-0152 AMMONIU M IRON II SULFATE HEXA 0.01 2.00 
.. RM-3079 TEST TUBES 16x100 10.00 42062 .00 1.70 
LABOR Anaerobe Lab Labo r Rate 10.00 
.. OVERHEAD FACTORY OVERHEAD 10.00 
. . W P-1470 HUNGATE ASS EMBLED 10.00 54758 .00 
. RM-1470 HUNGAT E CAPS- BLACK 10.00 18400 .00 0.50 
. RM-1480 HUNGATE STOPPER S 10.00 1.40 
. .. LBR-0020 CONTRACT CAP/STOPPE R ASSEM 10.00 
. RM-1598 LABELS- AS TH ERMAL 1.00 86667 .00 0.06 
WP-PACK- 723 Tota l 5.30 
4/8/19 at 09:49:06.76 Page: 1 
Anaerobe Systems 
Bill of Materials Report 
As of Apr 8, 2019 
Filter Criteria includes: 1) Item ID's from WP-EA-723 to WP-EA-723. Report order is by Item ID. Report is printed in Detail format with with shortened 
descriptions. 
Item ID 
W P-EA-723 
. W P-MED-723 
.. RM-0525 
. . RM-3480 
. . RM-0930 
.. RM-1580 
.. RM-3350 
. . RM-2020 
.. RM-1320 
.. RM-1720 
.. RM-0152 
. RM-3079 
. LABOR 
. OVERHEAD 
. W P-1470 
. . RM-1470 
.. RM-1480 
.. LBR-0020 
WP-EA-723 Tota l 
It em Desc riptio n 
CERVIS MEDIUM 
CERVIS MEDIUM 
BRAIN HEART INFUSION-PORCINE 
YEAST EXTRAC T TECH GRADE 
CYST EINE-SIGMA 
JOSAM YCIN 
VANCOM YCIN 
NEOMYCIN TRISULFATE 
GELLAN GUM 
MAGN ESIUM SULFATE HEPTAHYD 
AMMONIUM IRON II SULFATE HEXA 
TEST TUBES 16x100 
Anaerobe Lab Labo r Rate 
FACTORY OVERHEAD 
HUNGATE ASS EMBLED 
HUNGATE CAPS- BLACK 
HUNGATE STOPPER S 
CONTRACT CAP/STOPPER ASSEM 
Qty Needed Qty on Hand Est Cost 
0.01 
0.26 873.00 0.09 
0.04 1791 .76 0.00 
0.01 2327 .77 0.00 
0.00 0.21 0.03 
0.00 31.55 0.00 
0.00 43 .23 0.00 
0.03 4248 .00 0.01 
0.00 1465.45 0.00 
0.00 2.00 
1.00 42062 .00 0.17 
1.00 
1.00 
1.00 54758 .00 
1.00 18400 .00 0.05 
1.00 0.14 
1.00 
0.50 
